View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2021

NeuExcell and Spark partner to develop gene therapy for Huntington’s

Under the agreement, Spark will access the neuro-regenerative gene therapy platform of NeuExcell to develop the new treatment.

NeuExcell Therapeutics has entered a partnership with Roche Group member, Spark Therapeutics, to develop safe and efficient gene therapy for Huntington’s disease (HD) patients.

As per the agreement, Spark will obtain access to NeuExcell’s neuro-regenerative gene therapy platform, as well as its expertise and will work with the company’s research team to develop the programme.

Furthermore, Spark holds an option to licence the exclusive global rights of NeuExcell’s HD programme.

NeuExcell is eligible for upfront, licence fees, research and development (R&D) and sales milestone payments of up to nearly $190m from Spark.

Spark will also make royalty payments for the product to NeuExcell.

NeuExcell Therapeutics CEO Ronald HW Lorijn said: “We are excited to collaborate with Spark Therapeutics.

“Their in-house know-how and capabilities to develop gene therapies that may have the potential to slow, halt or cure neurological diseases and seek to enhance the industry standard for AAV engineering, making them an ideal partner to accelerate our HD programme.”

The neuro regenerative gene therapy platform of NeuExcell is based on transcription factor-based trans-differentiation technology.

This platform can potentially reprogramme endogenous glial cells such as astrocytes into functional new neurons. Astrocytes enclose neurons and frequently become reactive when neurons are damaged or die.

Neurons do not divide to regenerate themselves but glial cells are a renewable source to create new neurons at the damage site and at levels required to offer a significant therapeutic effect, NeuExcell noted.

The company is developing adeno-associated viruses (AAVs)-based neuro-regenerative gene treatments to revive functional new neurons at the area of neurodegeneration.

An incurable and hereditary brain disorder, HD is caused by one defective gene on chromosome 4.

The disease impacts various brain parts, affecting movement, behaviour as well as cognition.

In 2019, Roche signed a definitive merger agreement to acquire all outstanding shares of Spark for $114.50 per share, corresponding to a total of around $4.8bn on a fully diluted basis.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology